Hua Bao

4.8k total citations · 1 hit paper
137 papers, 2.7k citations indexed

About

Hua Bao is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Hua Bao has authored 137 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Cancer Research, 56 papers in Oncology and 54 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Hua Bao's work include Cancer Genomics and Diagnostics (72 papers), Lung Cancer Treatments and Mutations (43 papers) and Genetic factors in colorectal cancer (22 papers). Hua Bao is often cited by papers focused on Cancer Genomics and Diagnostics (72 papers), Lung Cancer Treatments and Mutations (43 papers) and Genetic factors in colorectal cancer (22 papers). Hua Bao collaborates with scholars based in China, Canada and United States. Hua Bao's co-authors include Yang Shao, Xue Wu, Paul Stothard, Qiuxiang Ou, Le Luo Guan, Xiaonan Wang, Xiaoling Tong, Yan Wang, Caicun Zhou and Yi Xiang and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Hua Bao

123 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients

2018 390 citations Zhe Yang, Nong Yang et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Hua Bao

Since Specialization

Citations

This map shows the geographic impact of Hua Bao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hua Bao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hua Bao more than expected).

Fields of papers citing papers by Hua Bao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hua Bao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hua Bao. The network helps show where Hua Bao may publish in the future.

Co-authorship network of co-authors of Hua Bao

This figure shows the co-authorship network connecting the top 25 collaborators of Hua Bao. A scholar is included among the top collaborators of Hua Bao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hua Bao. Hua Bao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The differences in molecular profiles and survival outcomes between early-onset and late-onset glioblastoma multiforme 2025 ·Genes & Diseases ·Yukui Wei, Xiaolong Wu, Hua Bao, (unknown), (unknown), (unknown), (unknown), (unknown), Ye Cheng, Xinru Xiao	0
2	Utility of liquid biopsy for predicting cancer type and informing treatment of carcinoma with unknown primary. 2024 ·Journal of Clinical Oncology ·Hua Bao, (unknown), (unknown), (unknown), (unknown), (unknown), Xue Wu, Yang Shao	0
3	Early detection, clinicopathological subtyping and prognosis prediction for patients with endometrial cancer using fragmentoimcs-based liquid-biopsy assay. 2024 ·Journal of Clinical Oncology ·(unknown), Hui Zhou, (unknown), (unknown), Wanxiangfu Tang, (unknown), (unknown), Hua Bao, Zhongqiu Lin, (unknown)	1
4	Comprehensive characterization of PKHD1 mutation in human colon cancer 2024 ·Cancer Medicine ·Lu Han, (unknown), (unknown), Wanxiangfu Tang, Hua Bao, Yue Wang, (unknown), (unknown), (unknown)	1
5	Clonal dynamics and Stereo-seq resolve origin and phenotypic plasticity of adenosquamous carcinoma 2023 ·npj Precision Oncology ·Ruiying Zhao, Yunhua Xu, Yedan Chen, (unknown), Fei Teng, Sha Liao, Shengnan Chen, Qian Wu, Chan Xiang, (unknown), (unknown), Jikai Zhao, Hairong Bao, Hua Bao, Yang Shao, Shun Lü, Yuchen Han	3
6	Pan‐cancer molecular analysis of EGFR large fragment deletion in the Asian population 2023 ·Cancer Medicine ·Jun Pu, (unknown), Ruoying Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Sanyuan Tang, (unknown)	2
7	Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics 2023 ·Cancer Research Communications ·Siwei Wang, (unknown), Jing You, (unknown), (unknown), Peng Chen, Wanxiangfu Tang, Hua Bao, (unknown), Xue Wu, Yang Shao, Jie Wang, (unknown), Lin Xu, Rong Yin	12
8	Multidimensional Cell-Free DNA Fragmentomic Assay for Detection of Early-Stage Lung Cancer 2022 ·American Journal of Respiratory and Critical Care Medicine ·Siwei Wang, (unknown), Ming Li, Hua Bao, Xin Chen, Meng Zhu, Rui Liu, (unknown), S Samuel Yang, Xue Wu, Yang Shao, Lin Xu, Rong Yin	43
9	Clinical and molecular characteristics of kinase domain duplications across diverse cancer types in the Chinese population 2022 ·Cancer Medicine ·(unknown), Ruoying Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Yang Li, Ying Zhang, Qingqing Ding	3
10	Sensitive detection of stage I lung adenocarcinoma using plasma cell-free DNA breakpoint motif profiling 2022 ·EBioMedicine ·Wei Guo, Xin Chen, Rui Liu, Naixin Liang, Qianli Ma, Hua Bao, (unknown), Xue Wu, S Samuel Yang, Yang Shao, Fengwei Tan, Qi Xue, Shugeng Gao, Jie He	32
11	Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer 2022 ·Journal of Oncology ·(unknown), Chong Li, (unknown), (unknown), Sisi Liu, (unknown), Wanxiangfu Tang, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, (unknown), Yixiang Zhang, Yuezhen Wang	3
12	Molecular landscape and therapeutic alterations in Asian soft‐tissue sarcoma patients 2022 ·Cancer Medicine ·Meifu Gan, Chen Zhang, (unknown), Yue Wang, Hua Bao, Ruoying Yu, Rui Liu, Xue Wu, Yang Shao, (unknown), (unknown)	6
13	Identification of TCR rearrangements specific for genetic alterations in EGFR-mutated non-small cell lung cancer: results from the ADJUVANT-CTONG1104 trial 2022 ·Cancer Immunology Immunotherapy ·Cunte Chen, Si‐Yang Maggie Liu, Yedan Chen, Qiuxiang Ou, Hua Bao, Ling Xu, Yikai Zhang, Jia‐Tao Zhang, (unknown), Qing Zhou, Xue‐Ning Yang, Yang Shao, Yi‐Long Wu, Si‐Yang Liu, Yangqiu Li	1
14	Somatic Alteration Characteristics of Early-Onset Gastric Cancer 2022 ·Journal of Oncology ·(unknown), Feng Tao, (unknown), (unknown), Hua Bao, Xue Wu, Yang Shao, Liangjie Chi, (unknown)	8
15	Genomic Profiling Reveals Novel Predictive Biomarkers for Chemo-Radiotherapy Toxicity and Efficacy in Non-Small-Cell Lung Cancer 2021 ·International Journal of Radiation OncologyBiologyPhysics ·Kewen He, (unknown), (unknown), Jie Yin, (unknown), Dezhi Mu, Shanshan Tang, Li Li, Hua Bao, Xue Wu, (unknown), Yang Shao, Jinming Yu, Shuanghu Yuan	2
16	Genomic characterization and outcome evaluation of kinome fusions in lung cancer revealed novel druggable fusions 2021 ·npj Precision Oncology ·Binghao Li, Hao Qu, Jing Zhang, Weibo Pan, Meng Liu, Xiaobo Yan, (unknown), Xuexin He, Lin Dong, Sisi Liu, (unknown), Yong Wu, Qiuxiang Ou, Hua Bao, (unknown), Xue Wu, Yang Shao, Nong Lin	17
17	Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M–positive Non–Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study 2020 ·Clinical Cancer Research ·Ligang Xing, Yueyin Pan, Yuankai Shi, Yongqian Shu, Jifeng Feng, Wěi Li, Lejie Cao, Lifeng Wang, Wei Gu, Yong Song, Puyuan Xing, Yutao Liu, Wen Gao, Jiuwei Cui, (unknown), Rutian Li, Hua Bao, Yang Shao, Jinming Yu	28
18	Green tea polyphenols supplementation alters immunometabolism and oxidative stress in dairy cows with hyperketonemia 2020 ·Animal nutrition ·Yanfen Ma, (unknown), (unknown), Muyang Li, Hongyu Dai, Hua Bao, Guijie Zhang, Lei Zhao, Chunhua Zhang, Jing Yi, Yusheng Liang	21
19	Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer 2019 ·Clinical Cancer Research ·Wenfeng Fang, Yuxiang Ma, Jiani C. Yin, Shaodong Hong, Huaqiang Zhou, Ao Wang, Fufeng Wang, Hua Bao, Xue Wu, Yunpeng Yang, Yan Huang, Hongyun Zhao, Yang Shao, Li Zhang	139
20	Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients breakdown → 2018 ·Clinical Cancer Research ·Zhe Yang, Nong Yang, Qiuxiang Ou, Yi Xiang, Tao Jiang, Xue Wu, Hua Bao, Xiaoling Tong, Xiaonan Wang, Yang Shao, Yunpeng Liu, Yan Wang, Caicun Zhou	390

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact